The study aims to: 1) formulate and manufacture pharmaceutically elegant, safe, stable, and effective dosage forms from Philippine medicinal plant materials; 2) undertake quality control tests; 3) utilize indigenous pharmaceutical excipients or additives in formulation; and 4) set specifications for raw materials, processes, and finished products.
Actual formulation trials on selected Philippine medicinal plants namely lagundi, niyog-niyogan, sambong, yerba buena, ipil-ipil, tsaang-gubat, makahiya, mangosteen, balanoy, damong maria and akapulko will be performed. Dosage formulation, testing of the medicinal plant dosage forms manufactured, and patent rights application of the herbal formulations will be the main procedure that will be undergone by each herbal plant. Submission of annual progress reports on Lagundi, Yerba Buena, Tsaang-gubat, and Sambong tablets for relisting with the Bureau of Food and Drugs have been accomplished. Formulation and manufacture of tablets, suspensions, syrups, tinctures, and lotion have been further studied for their stability.
The project has also developed quality control standards and specifications and pediatric dosage forms while statistical analysis of results is on-going. Twelve regional pharmacists under the training program of the MOH in collaboration with NSTA-UP Pilot Plant were trained on the manufacture of herbal tablets. They will be utilized for the market acceptability study of the Philippine Herbal Group Inc. (PHGI).